2026-04-17T20:00:58Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2281892026-04-12T18:03:50Zcom_2072_1057col_2072_478858col_2072_478916col_2072_478917

XVII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2024 ECTRIMS Congress (II) Fernández, Óscar Arés, Adrián Agüera, Eduardo Aladro, Yolanda Alonso, Ana Arroyo, Rafael Brieva, Luis Calles, Carmen Belén Caminero, Ana Castillo Triviño, Tamara Costa Frossard, Lucienne Eichau, Sara Ángel Hernández, Miguel Landete, Lamberto Llaneza, Miguel Llufriu, Sara Meca Lallana, José E. Meca Lallana, Virginia Moral, Ester Oreja Guevara, Celia María Prieto, José Romero Pinel, Lucía María Vilaseca, Andreu Rodríguez Antiguedad, Alfredo Esclerosi múltiple Malalties cerebrovasculars Revisions mèdiques Multiple sclerosis Cerebrovascular disease Periodic health examinations Introduction: The XVII edition of the post-European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting was held on 4-5 October 2024 in Madrid. This event was attended by Spanish neurologists specialized in multiple sclerosis (MS), who presented a summary of the most relevant advances discussed at the ECTRIMS congress, held days before in Copenhagen.Aim: To summarize the main new findings in clinical research on MS.Content and Conclusions: The immunological changes throughout life and in response to MS treatments were analyzed. The impact of aging was also discussed, along with new developments related to symptomatic treatments, physical exercise, fatigue, and sleep disorders. Emphasis was placed on addressing ongoing challenges in measuring therapeutic failure and managing treatments for secondary progressive MS. Additionally, data from registries and real-world studies were presented, including new analyses on cladribine, highlighting the need to collect safety information. Regarding immune reconstitution therapies, mechanisms of action and the immune system's reconstitution process after treatment were explored. Finally, regarding therapeutic innovations, the first results from chimeric antigen receptor (CAR)-T cell therapy studies in MS were reported, representing a promising advancement in disease management. 2026-03-17T14:20:41Z 2026-03-17T14:20:41Z 2026-01-21 2026-02-24T16:11:01Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 1576-6578 https://hdl.handle.net/2445/228189 41609133 eng Reproducció del document publicat a: https://doi.org/10.31083/RN39228 Revista de Neurología, 2026, vol. 81, num. 1,39228 https://doi.org/10.31083/RN39228 cc-by (c) Fernández, Óscar et al., 2026 https://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess 14 p. application/pdf IMR Press Comunicacions a congressos (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))